STAT5b as molecular target in pancreatic cancer-inhibition of tumor growth, angiogenesis, and metastases

Neoplasia (United States)

Volumn 14, Issue 10, 2012, Pages 915-925

  Moser, Christian ^a   Ruemmele, Petra ^b   Gehmert, Sebastian ^a   Schenk, Hedwig ^a   Kreutz, Marina P ^b   Mycielska, Maria E ^a   Hackl, Christina ^a   Kroemer, Alexander ^a   Schnitzbauer, Andreas A ^a   Stoeltzing, Oliver ^c   Schlitt, Hans J ^a   Geissler, Edward K ^a   Lang, Sven A ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; SHORT HAIRPIN RNA; STAT5B PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NICK END LABELING; NONHUMAN; PANCREAS ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VASCULARIZATION; WESTERN BLOTTING;

EID: 84867777560     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12878     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364, 1817-1825.
3. Stathis A and Moore MJ (2010). Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7, 163-172.
4. Vincent A, Herman J, Schulick R, Hruban RH, and Goggins M (2011). Pancreatic cancer. Lancet 378, 607-620.
5. Cree IA (2011). Cancer biology. Methods Mol Biol 731, 1-11.
6. Santos CI and Costa-Pereira AP (2011). Signal transducers and activators of transcription-from cytokine signalling to cancer biology. Biochim Biophys Acta 1816, 38-49.
7. Yu H and Jove R (2004). The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4, 97-105.
8. Glienke W, Hausmann E, and Bergmann L (2011). Targeting STAT3 signaling in pancreatic cancer promotes antiapoptotic gene expression. Pancreas 40, 323-324.
9. Huang C, Jiang T, Zhu L, Liu J, Cao J, Huang KJ, and Qiu ZJ (2011). STAT3- targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. Int J Oncol 38, 1637-1644.
10. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, et al. (2003). Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22, 319-329.
11. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, and Nevalainen MT (2003). Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278, 27287-27292.
12. Kazansky AV, Spencer DM, and Greenberg NM (2003). Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res 63, 8757-8762.
13. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, et al. (2011). Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 29, 2448-2458.
14. Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, Johnson KJ, Neilson LM, Liu C, Brill KL, et al. (2010). Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res 70, 1711-1721.
15. Lee TK, Man K, Poon RT, Lo CM, Yuen AP, Ng IO, Ng KT, Leonard W, and Fan ST (2006). Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelialmesenchymal transition. Cancer Res 66, 9948-9956.
16. Liang QC, Xiong H, Zhao ZW, Jia D, Li WX, Qin HZ, Deng JP, Gao L, Zhang H, and Gao GD (2009). Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells. Cancer Lett 273, 164-171.
17. Mao Y, Li Z, Lou C, and Zhang Y (2011). Expression of phosphorylated Stat5 predicts expression of cyclin D1 and correlates with poor prognosis of colonic adenocarcinoma. Int J Colorectal Dis 26, 29-35.
18. Xiong H, Su WY, Liang QC, Zhang ZG, Chen HM, Du W, Chen YX, and Fang JY (2009). Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab Invest 89, 717-725.
19. Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB, and Grandis JR (2008). Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res 14, 7682-7690.
20. Chen H, Ye D, Xie X, Chen B, and Lu W (2004). VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 94, 630-635.
21. Jackerott M, Moldrup A, Thams P, Galsgaard ED, Knudsen J, Lee YC, and Nielsen JH (2006). STAT5 activity in pancreatic β-cells influences the severity of diabetes in animal models of type 1 and 2 diabetes. Diabetes 55, 2705-2712.
22. Kataoka TR, Ioka T, Tsukamoto Y, Matsumura M, Ishiguro S, and Nishizawa Y (2007). Nuclear expression of STAT5 in intraductal papillary mucinous neoplasms of the pancreas. Int J Surg Pathol 15, 277-281.
23. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, et al. (2007). Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxiainducible factor-1α autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13, 6459-6468.
24. Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler EK, and Stoeltzing O (2010). Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer 10, 668.
25. Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, and Lang SA (2011). Targeting FGFR/PDGFR/ VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 10, 2157-2167.
26. Gottfried E, Rogenhofer S, Waibel H, Kunz-Schughart LA, Reichle A, Wehrstein M, Peuker A, Peter K, Hartmannsgruber G, Andreesen R, et al. (2011). Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids. Cancer Chemother Pharmacol 67, 117-126.
27. Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, and Stoeltzing O (2009). Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49, 523-532.
28. Bernaciak TM, Zareno J, Parsons JT, and Silva CM (2009). A novel role for signal transducer and activator of transcription 5b (STAT5b) in β1-integrinmediated human breast cancer cell migration. Breast Cancer Res 11, R52.
29. Buchler P, Reber HA, Tomlinson JS, Hankinson O, Kallifatidis G, Friess H, Herr I, and Hines OJ (2009). Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia 11, 196-206.
30. Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD, Le X, Wei D, Huang S, and Xie K (2012). A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res 72, 655-665.
31. Koch M, Dettori D, Van Nuffelen A, Souffreau J, Marconcini L, Wallays G, Moons L, Bruyere F, Oliviero S, Noel A, et al. (2009). VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis. J Pathol 219, 356-364.
32. Kurahara H, Takao S, Maemura K, Shinchi H, Natsugoe S, and Aikou T (2004). Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 10, 8413-8420.
33. Garcea G, Lloyd TD, Gescher A, Dennison AR, Steward WP, and Berry DP (2004). Angiogenesis of gastrointestinal tumours and their metastases-a target for intervention? Eur J Cancer 40, 1302-1313.
34. Hanahan D and Folkman J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
35. Kim HJ, Tsoyi K, Heo JM, Kang YJ, Park MK, Lee YS, Lee JH, Seo HG, Yun-Choi HS, and Chang KC (2007). Regulation of lipopolysaccharide-induced inducible nitric-oxide synthase expression through the nuclear factor-κB pathway and interferon-β/tyrosine kinase 2/Janus tyrosine kinase 2-signal transducer and activator of transcription-1 signaling cascades by 2-naphthylethyl-6,7-dihydroxy- 1,2,3,4-tetrahydroisoquinoline (THI 53), a new synthetic isoquinoline alkaloid. J Pharmacol Exp Ther 320, 782-789.
36. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461.
37. Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamasaki S, and Chayama K (2003). Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 26, 344-349.
38. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, and Post S (2002). High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25, 122-129.
39. Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, Buchler MW, Weitz J, and Koch M (2011). Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 11, 286.
40. Yachida S and Iacobuzio-Donahue CA (2009). The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med 133, 413-422.
41. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, et al. (2010). Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 17, 481-493.
42. Man S, Munoz R, and Kerbel RS (2007). On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev 26, 737-747.
43. Downward J (2004). PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15, 177-182.